The latest announcement is out from Collegium Pharmaceutical ( (COLL) ).
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue. The company completed the integration of Ironshore Therapeutics and plans targeted investments in Jornay PM to drive growth, aiming for significant top- and bottom-line growth and long-term shareholder value.
More about Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. is a biopharmaceutical company that focuses on responsible pain management medications and neuropsychiatry, with its lead product Jornay PM for ADHD. The company aims to expand its commercial portfolio and is headquartered in Stoughton, Massachusetts.
YTD Price Performance: 1.78%
Average Trading Volume: 431,079
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $923M
For an in-depth examination of COLL stock, go to TipRanks’ Stock Analysis page.
